Investor Relations

Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis

Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results